Electra Therapeutics (ETRA) – Investment Analysts’ Weekly Ratings Changes

Electra Therapeutics (NASDAQ: ETRA) recently received a number of ratings updates from brokerages and research firms:

• 10/26/2026 – Electra Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $30.00 price target on the stock.
• 10/22/2026 – Electra Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $36.00 price target on the stock.
• 10/14/2026 – Electra Therapeutics was upgraded by Zacks Research to “hold”.
• 10/13/2026 – Electra Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $32.00 price target on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by Evercore. They set an “outperform” rating and a $36.00 price target on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $32.00 price target on the stock.
• 10/13/2026 – Electra Therapeutics was upgraded by Evercore to “strong-buy”.
• 9/26/2026 – Electra Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Buying and Selling at Electra Therapeutics

In related news, Director Carl L. Gordon acquired 1,333,333 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the acquisition, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This trade represents a 35.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Orbimed Advisors Llc acquired 1,333,333 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was bought at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the acquisition, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. The trade was a 35.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.